James Lu, MD;PhD

James Lu, MD, PhD is the CEO of Helix, the leading population genomics and viral surveillance company. He leads the company’s day to day operations and serves on the Board of Directors. Prior to this role, he acted as President and Chief Scientific Officer where he led the development of Helix’s Exome+® assay, established the company’s CLIA/CAP lab and created the Helix Research Platform. Under James’ leadership, Helix was awarded the first and only FDA authorization for its whole exome sequencing platform. He also drove Helix’s large-scale COVID-19 testing and viral surveillance program, securing partnerships with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program and with the Centers for Disease Control and Prevention (CDC). James is a graduate of Stanford University where he earned a BS and MS in Chemical Engineering and of Baylor College of Medicine where he earned his MD and PhD in computational biology.